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Abstract
Previous epidemiologic studies found increased prevalences of type 2 diabetes mellitus in
populations exposed to high levels of inorganic arsenic (iAs) in drinking water. Although results of
epidemiologic studies in low-exposure areas or occupational settings have been inconclusive,
laboratory research has shown that exposures to iAs can produce effects that are consistent with type
2 diabetes. The current paper reviews the results of laboratory studies that examined the effects of
iAs on glucose metabolism and describes new experiments in which the diabetogenic effects of iAs
exposure were reproduced in a mouse model. Here, weanling male C57BL/6 mice drank deionized
water with or without the addition of arsenite (25 or 50 ppm As) for 8 weeks. Intraperitoneal glucose
tolerance tests revealed impaired glucose tolerance in mice exposed to 50 ppm As, but not to 25 ppm
As. Exposure to 25 and 50 ppm As in drinking-water resulted in proportional increases in the
concentration of iAs and its metabolites in the liver and in organs targeted by type 2 diabetes,
including pancreas, skeletal muscle and adipose tissue. Dimethylarsenic was the predominant form
of As in the tissues of mice in both 25 and 50 ppm groups. Notably, the average concentration of
total speciated arsenic in livers from mice in the 50 ppm group was comparable to the highest
concentration of total arsenic reported in the livers of Bangladeshi residents who had consumed water
with an order of magnitude lower level of iAs. These data suggest that mice are less susceptible than
humans to the diabetogenic effects of chronic exposure to iAs due to a more efficient clearance of
iAs or its metabolites from target tissues.
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Arsenic (As) is a naturally occurring toxic metalloid found in the environment in both inorganic
and organic forms. Inorganic As (iAs) is the predominant form of As in surface and
underground water reservoirs. Drinking-water containing high levels of iAs and industrial
pollution are major sources of iAs exposure for millions of people throughout the world.
Countries where As levels in drinking-water have been found to exceed the World Health
Organization Standard of 10 μg/L include Argentina, Australia, Bangladesh, Chile, China,
Hungary, India, Mexico, Peru, Taiwan, and the United States of America (WHO, 2001).
Adverse health effects associated with chronic exposure to iAs have been documented in most
of these countries. It is estimated that more than 50 million people in Bangladesh (BGS,
2001) and 13 million residents of the U.S. (Focazio et al., 1999) are exposed to drinking-water
with iAs concentrations at or above 10 μg/L. iAs is classified as a human carcinogen (IARC,
1987). Numerous epidemiologic studies have associated chronic exposure to iAs with
increased prevalence of cancers of the skin, bladder, liver, lung, and stomach (Bates et al.,
1995; Bates et al., 1992; Chen et al., 1992; Chen et al., 1985; Chiang et al., 1988; Chiou et
al., 1995; Guo et al., 1997; Hopenhayn-Rich et al., 1996; Hopenhayn-Rich et al., 1998; Lewis
et al., 1999; Smith et al., 1998; Smith et al., 1992; Tseng et al., 1968; Tsuda et al., 1995; Wu
et al., 1989). Previous research of the effects of chronic exposure to iAs has focused primarily
on its carcinogenic potential. However, chronic exposures to iAs from the environment or in
occupational settings have also been linked to non-carcinogenic diseases, including peripheral
vascular disease, cardiovascular and cerebrovascular diseases (Chen et al., 1995; Chen et al.,
1996; Chiou et al., 1997; Engel et al., 1994; Thomas and Goyer, 1995; Tseng et al., 1995;
Tseng et al., 1997), hypertension (Chen et al., 1995), goiter (Chang et al., 1991), hepatomegaly
(Santra et al., 1999), respiratory system dysfunction (Mazumder et al., 2000), nervous system
dysfunction (Bencko et al., 1977; Chisolm Jr. and Thomas, 1983; Masahiko and Hideyasu,
1973), and diabetes mellitus (Lai et al., 1994; Rahman et al., 1998; Rahman et al., 1999; Tseng
et al., 2000).
Epidemiologic Evidence of the Association Between Chronic Exposure to iAs and Diabetes
Mellitus
Studies examining the role of iAs exposure on the development of diabetes represent a growing
area of research. Diabetes refers to a group of metabolic diseases characterized by systemic
disruption of glucose homeostasis. Insulin-dependent (type 1) diabetes is caused by the
autoimmune destruction of insulin-producing pancreatic β-cells, resulting in a severe
deficiency of circulating insulin (hypoinsulinemia) and the concomitant elevation of blood
glucose (hyperglycemia). Non-insulin-dependent (type 2) diabetes is characterized by
hyperglycemia due to the resistance of peripheral tissues such as adipose tissue, skeletal muscle
and the liver to insulin stimulus and a relative insufficiency of insulin production by pancreatic
β-cells. Gestational diabetes (type 3) is similar to type 2 diabetes with respect to its pathogenesis
and clinical symptoms; however, it occurs in women during pregnancy and usually improves
or disappears after child birth. The pathogenesis of arsenic-induced diabetes is unknown.
Diagnosis of diabetes in populations exposed to iAs has relied primarily on measurements of
fasting blood glucose, glucosuria, glycosylated hemoglobin (HbA1c), oral glucose tolerance
tests, clinical history of the disease or mortality linked to diabetes. The results of these
diagnoses are suggestive of insulin resistance and type 2 diabetes; however, β-cell dysfunction
cannot be ruled out.
The association between iAs exposure via drinking-water and increased risk of developing
type 2 diabetes was first reported in Taiwan by Lai and associates (1994). These authors found
a twofold increase in the prevalence of diabetes mellitus among residents of arseniasis-endemic
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areas as compared to residents in non-endemic areas. Furthermore, a significant dose-response
relationship was found between cumulative exposure to iAs and the prevalence of diabetes.
The link between diabetes mellitus and consumption of water containing iAs was later
confirmed by several cross-sectional and cohort studies from Taiwan (Tseng et al., 2000) and
Bangladesh (Rahman et al., 1998; Rahman et al., 1999). Other studies have examined the
association between exposure to iAs in occupational settings and the occurrence of symptoms
that are consistent with diabetes (Jensen and Hansen, 1998; Rahman and Axelson, 1995;
Rahman et al., 1996). These studies were retrospective in nature and primarily used death
certificates as their diagnostic criteria. It should be noted that some of the epidemiologic studies
linking chronic exposures to iAs with type 2 diabetes suffer serious problems associated mainly
with insufficient assessment of exposure to iAs, inadequate diagnosis of diabetes or lack of
dose-response data. A critical review of these studies has recently been published by Navas-
Acien and associates (2006). These authors concluded that methodological problems limit the
causal interpretation of the moderately strong association between iAs exposure and diabetes
in Taiwan and Bangladesh. Overall, the epidemiologic evidence was regarded as insufficient
and inadequate to establish causality.
Laboratory Studies of the Effects of As on Glucose Metabolism
The effects of As on glucose metabolism have been examined by numerous laboratory studies.
However, it should be noted that As has traditionally been used, along with other chemical or
physical agents, as an acute stressor in research of stress-mediated cell signaling or stress-
induced responses in various metabolic pathways, including the pathways of carbohydrate
metabolism. Studies in this area of research have examined insulin secretion and glucose
metabolism in cultured cells or laboratory animals exposed to highly toxic concentrations of
As, which are incompatible with chronic exposures in humans. Therefore, data from these
studies cannot be evaluated with respect to possible mechanisms of diabetes induced by
environmental or occupational exposures and attempts to do so would inevitably yield
confusing results (Navas-Acien et al., 2006). The following is a brief contextual review of
laboratory studies that have examined the effects of As on processes directly related to glucose
homeostasis.
Effects on glucose uptake—Insulin-stimulated glucose uptake (ISGU) by skeletal muscle
and adipose tissue is a key process responsible for the normalization of postprandial blood
glucose levels. Results of early laboratory studies suggest that disruption of ISGU is a potential
mechanism responsible for the development of type 2 diabetes in response to chronic exposures
to iAs. In 1985, Frost and associates reported that phenylarsine oxide (PAO), a aromatic
derivative of trivalent arsenic (AsIII), is a potent inhibitor (Ki = 7 μM) of ISGU by murine 3T3-
L1 adipocytes (Frost and Lane, 1985). Micromolar concentrations of PAO have also been
reported to inhibit ISGU by isolated rat skeletal muscle (Henriksen and Holloszy, 1990; Sowell
et al., 1988). Later reports have shown that the inhibition of ISGU in 3T3-L1 adipocytes treated
with PAO is associated with hypophosphorylation of two endogenous phosphoproteins (p24
and p240), possible components of the insulin-stimulated signal transduction pathway (Frost
and Lane, 1985). Notably, PAO does not interfere with the insulin-dependent phosphorylation
of the insulin receptor or interact directly with glucose transporters (Frost et al., 1987; Frost
and Lane, 1985).
The effects of PAO and other arsenicals on basal (insulin independent) glucose uptake have
also been examined by several studies that focused mostly on stress-induced responses in
cultured cells. These studies used high concentrations of arsenicals that are cytotoxic for most
cell types. Here, PAO (50 μM) or iAsIII (200–1000 μM) have been shown to stimulate basal,
insulin-independent, glucose uptake in baby hamster kidney (BHK) cells (Pasternak et al.,
1991; Sviderskaya et al., 1996; Warren et al., 1986; Widnell et al., 1990), bovine chromaffin
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cells (Fladeby and Serck-Hanssen, 1999), 3T3-L1 adipocytes (Bazuine et al., 2004; Bazuine
et al., 2003; Gould et al., 1989) and in L6 myotubes (McDowell et al., 1997). A modest 1–3
fold increase in basal glucose uptake was typically found with no effect on the translocation
of GLUT4, an insulin-sensitive glucose transporter, to the plasma membrane. Only one study
showed an increased presence of GLUT4 at the plasma membrane of BHK cells in response
to treatment with PAO (35 μM) (Widnell et al., 1990). In contrast, two studies reported
inhibition of basal glucose uptake in Madin-Darby canine kidney (MDCK) cells treated with
25 μM PAO or 1000 μM iAsIII (Liebl et al., 1992) and in rat tubule kidney (RTK) cells treated
with 2 μM PAO (Liebl et al., 1995). The increase in basal glucose uptake by toxic
concentrations of PAO or iAsIII was associated with the activation of a stress response, p38
MAPK-mediated signal transduction pathway in several studies (Bazuine et al., 2004; Bazuine
et al., 2003; Fladeby and Serck-Hanssen, 1999). Phosphorylation of p38 MAPK has been
shown to increase intrinsic activity of GLUT4 transporters already present at the plasma
membrane, resulting in increased glucose uptake by cells (Somwar et al., 2002; Sweeney et
al., 1999). In several studies, toxic concentrations of iAsIII were used explicitly for their
capacity to activate the p38 MAPK pathway and to induce acute stress.
Data from previous studies indicate that an alternative mechanism for increased basal glucose
uptake by cells exposed to high concentrations of trivalent arsenicals may involve the activation
of phosphatidylinositol-3-kinase (PI-3K) and PI-3K-dependent phosphorylation of protein
kinase B (PKB/Akt). Increased PI-3K-mediated PKB/Akt phosphorylation has been reported
in cells exposed to toxic concentrations (200–500 μM) of iAsIII (McDowell et al., 1997; Souza
et al., 2001). Stress-induced phosphorylation of PKB/Akt is associated with the activation of
pro-survival mechanisms aimed at preventing apoptosis and promoting cell proliferation
(Dudek et al., 1997; Ibuki and Goto, 2000; Zhou et al., 2000). However, PKB/Akt
phosphorylation is also one of the key steps in the activation of GLUT4 transporters by insulin
(Kohn et al., 1996; Tanti et al., 1997). Thus, exposure to toxic concentrations of trivalent
arsenicals may mimic the action of insulin by activating the p-PKB/Akt-mediated glucose
transport in cells expressing GLUT4.
Taken together, studies examining glucose transport in cell culture systems suggest that acute
stress induced by exposures to toxic concentrations of trivalent arsenicals is associated with
p38- or p-PKB/Akt-mediated increase in basal, insulin-independent, glucose uptake. In
contrast, exposures to low micromolar concentrations of PAO inhibit ISGU. It should be noted
that PAO is not a metabolite of iAs and its chemical properties and metabolic fates differ from
those of iAs or its methylated metabolites. Therefore, while studies using subtoxic
concentrations of PAO may provide valuable insights into the diabetogenic effects of chronic
exposures to iAs, the significance of these studies for evaluation of the molecular mechanisms
underlying effects of iAs or its metabolites is limited.
The effects of physiologically relevant trivalent arsenicals, the known metabolites of iAs, on
ISGU and insulin-activated signal transduction have been examined in this laboratory. Here,
dose-dependent decreases in ISGU were observed in 3T3-L1 adipocytes exposed for 4 or 24
h to subtoxic concentrations of iAsIII, or the methylated metabolites of iAs, methylarsonite
(MAsIII) and dimethylarsinite (DMAsIII) (Walton et al., 2004). We have recently shown that
two of these arsenicals, iAsIII or MAsIII, inhibit the activity of 3-phosphoinositide dependent
kinase 1 (PDK-1) and the subsequent PDK-1-catalyzed phosphorylation of PKB/Akt (Paul et
al., submitted). Notably, DMAsIII inhibited GLUT4 translocation in insulin-activated
adipocytes by a mechanism independent of PKB/Akt phosphorylation. Results from other
laboratories suggest that metabolites of iAs may also interfere with glucose metabolism by
inhibiting α-ketoglutarate dehydrogenase or pyruvate dehydrogenase (Boquist et al., 1988;
Petrick et al., 2001), two rate limiting enzymes involved in the oxidative metabolism of
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carbohydrates. However, it is unclear whether concentrations of iAs metabolites in tissues of
chronically exposed individuals can reach levels necessary for inhibition of these enzymes.
Effects on β-cell function—Compared with data on glucose metabolism and insulin
signaling in mammalian cells exposed to trivalent arsenicals, much less information is available
on the effects of arsenicals on insulin production by β-cells. Insulin is a metabolic hormone
produced and secreted by β-cells in response to elevated blood glucose concentrations and is
responsible for the stimulation of glucose uptake by peripheral adipose and skeletal muscle
tissues as well as the suppression of gluconeogenesis in the liver. Insulin insufficiency has
deleterious effects on glucose homeostasis and contributes to the pathogenesis of type 1 and
type 2 diabetes. Several studies have examined the effects of arsenicals on pancreatic/duodenal
homeobox-1 (PDX-1, also identified as insulin upstream factor 1), a transcription factor that
binds to the promoter of the preproinsulin gene in response to elevated blood glucose
concentrations. PDX-1 DNA binding was found to be increased in isolated human islets and
MIN6 cells, a mouse β-cell line, treated with iAsIII for 30 min (Macfarlane et al., 1997). In
addition, iAsIII was found to promote PDX-1 activation and translocation to the nucleus, which
is a critical step in the stimulation of preproinsulin mRNA transcription (Elrick and Docherty,
2001; Macfarlane et al., 1999). However, both these studies used a toxic (1 mM) concentration
of iAsIII to induce stress-activated p38 MAPK, which is believed to play a role in regulating
insulin production in response to glucose stimulus. In contrast with the stimulatory effects of
millimolar iAsIII, toxic (5 mM) concentration of a pentavalent iAs, arsenate (iAsV), has been
shown to disrupt insulin secretion by interfering with pancreatic islet respiration (Ortsater et
al., 2002). Because of the acute nature of the exposure, the significance of these findings for
chronic environmental exposures is questionable. The effects of low micromolar
concentrations of iAsIII on β-cell function have recently been examined (Diaz-Villasenor et
al., 2006). The authors reported that exposures to a subtoxic (5 μM) concentration of iAsIII for
72 h inhibits glucose-stimulated expression of preproinsulin and insulin secretion by isolated
rat pancreatic islets. However, because DNA damage was used in this study as an indicator of
cytotoxicity, the actual effect of this exposure on cell viability is unclear.
Laboratory Studies in Animals
The potential mechanisms responsible for the diabetogenic effects associated with chronic
exposures to iAs provided by in vitro studies have not yet been validated by in vivo experiments.
Previous in vivo studies have examined blood glucose or insulin levels in goats, rats, or mice
after exposures to iAsV or iAsIII via food, drinking water or intraperitoneal injection (Biswas
et al., 2000; Cobo and Castineira, 1997; Ghafghazi et al., 1980; Hughes and Thompson,
1996; Izquierdo-Vega et al., 2006; Pal and Chatterjee, 2005, 2004a, b). The dose, duration and
form of As used in these studies have varied greatly, producing conflicting results and
confusing the interpretation of data with respect to environmental exposures to iAs in humans.
The effects of iAs exposure on glucose tolerance in mice have recently been examined in this
laboratory. The experimental section of this report describes the development of a mouse model
for diabetes induced by chronic exposure to iAs in drinking water. The diabetogenic effects of
iAs exposure are evaluated with respect to tissue retention and distribution of iAs metabolites.
Materials and methods
Chemicals
Sodium arsenite (99% pure) was purchased from Sigma-Aldrich (St. Louis, MO). Sodium
borohydride (NaBH4) was from EM Science (Gibbstown, NJ). Ultrapure phosphoric acid was
obtained from J.T. Baker (Phillipsburg, NJ). Sodium arsenate (96%, Sigma),
monomethylarsonate (MAsV), disodium salt (98%, Chem Service, West Chester, PA),
dimethylarsinic acid (DMAsV) (98%, Strem Chemicals, Inc., Newburyport, MA) and
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trimethylarsine oxide (TMAsVO, gift from Dr. William Cullen, UBC, Vancouver) were used
as standards for speciation analysis of As in mouse tissues. All other chemicals used were the
highest grade commercially available.
Animals
Four-week-old male weanling C57BL/6 mice were obtained from The Jackson Laboratory
(Bar Harbor, ME, USA) and housed five per cage with free access to food and drinking water
(see below). All mice were housed in polycarbonate cages with corn cob bedding in the
University of North Carolina Animal Facility (12 h light/dark cycle, 22 ± 1°C and humidity of
50 ± 10%), which is fully accredited by the American Association for Accreditation of
Laboratory Animal Care. Animals were allowed free access to food (Lab Diet 5058, Nutrition
International, Brentwood, MO) and deionized water (dH2O). Mice in two groups (5 animals
each) drank dH2O with the addition of iAsIII (25 or 50 ppm As). The third group (n = 5) drank
pure dH2O. Water containing iAsIII was freshly prepared every 3–4 days to minimize oxidation
to iAsV. Water consumption and body weights were monitored in all exposure groups every
week or two weeks, respectively.
Intraperitoneal Glucose Tolerance Test (IPGTT)
Mice were fasted 5 h prior to administration of the IPGTT. D-glucose (Sigma) was dissolved
in phosphate buffered saline and administered to mice via i.p. injection (2 g/kg). Samples of
whole-blood (2–3 μl each) were collected from a tail clip bleed immediately before and 15,
30, 60, 90, and 120 min after glucose injection. Blood glucose levels were measured using a
Freestyle Glucose Monitoring System (Abbott Laboratories, Abbott Park, IL.)
Speciation Analysis of As
Freshly dissected tissues were aliquoted into 2.0 ml cryotubes, snap frozen in liquid nitrogen
and stored at −70°C until analysis. Speciated arsenicals in tissues were determined by
automated hydride generation-atomic absorption spectrometry (HG-AAS) coupled with a
cryotrap. Tissues were digested overnight in 2 M ultrapure phosphoric acid (90°C) (Hughes
et al., 2005). The digestion converts all trivalent arsenicals to pentavalency. Phosphoric acid
in digested samples was neutralized by NaOH. L-cysteine was added to each sample at a final
concentration of 2%. For analysis of TMAsVO, samples were analyzed without cysteine
(Devesa, 2004). Arsines were generated from a 500 μl aliquot of the digested tissue, which
was injected into a flow of deionized water continuously mixed with a flow of 0.75M TRIS-
HCl buffer (pH 6) and a flow of 1% NaBH4 in 0.1% NaOH/0.02% antifoam B silicone
emulsion, all at the rate of 1 ml/min. Arsines were cryotrapped and separated by boiling points,
as previously described (Devesa, 2004). The content of As in arsines was determined using a
Perkin-Elmer model 5100 atomic absorption spectrometer equipped with a quartz
multiatomizer (Matousek et al., 2002). Under these conditions, this method routinely resolves
arsines generated from iAsV, MAsV, DMAsV, and TMAsVO. Five concentrations (0.05, 0.25,
0.5, 1 and 2.5 ng/ml) of each of these arsenicals were used to prepare calibration curves.
Arsenicals in tissue samples were identified by spiking with appropriate As standards at several
concentrations. The concentration of total speciated As for each tissue sample was calculated
as the sum of concentrations of iAsV, MAsV, DMAsV, and TMAsVO. In order to determine
the recovery of As during the HG-AAS analysis, the total As in selected tissues was analyzed
by graphite furnace (GF) AAS using a Perkin-Elmer model 5100 atomic absorption
spectrometer with an autosampler. For this analysis, tissues were microwave digested (CEM,
Model MARS 5) following the 3052 EPA method with some modifications. Briefly, 0.1 g of
tissue was completely digested in 70% nitric acid in a total volume of 10 ml. A 1-ml aliquot
of each digestate was diluted with 20% nitric acid to a final volume of 5 ml. A 40 μl aliquot
of this solution was injected into the GF along with 10 μl of a chemical modifier (5 μg of
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palladium and 5 μg of magnesium nitrate in 2% nitric acid). The GF program included a drying
step at 130° C for 40s, ashing step at 1300° C for 40s, and atomization step at 2300° C for 3s.
The recovery of As was calculated as the total speciated As concentration (determined by HG-
AAS) divided by the total As concentration (determined by GF-AAS) for each tissue. HG-
AAS was also used for analysis of As species in all lots of the laboratory diet used in this study.
Results
Water Consumption and Body Weights
Water consumption by mice in each exposure group was measured twice a week throughout
the course of the study. An initial decline in water intake, possibly indicative of an acclimation
period, was noted for all groups (Fig 1A). However, water consumption stabilized by week 2
for the 25 ppm and 50 ppm groups, and by week 3 for the control group. Control mice consumed
an average of 5.0 ml of water per day (ml/d). Mice in the 25 ppm and 50 ppm group consumed
significantly less water: 3.8 ml and 2.5 ml per day, respectively (Fig 1B). Average daily As
intake in drinking water per mouse was estimated based on the water consumption. Mice in
the 25 ppm group ingested 94.7 μg of As/day via drinking water while mice in the 50 ppm
group ingested 125.3 μg of As/day (Fig 1C). The laboratory diet was a minor source of As.
The total As concentration in several lots of the diet ranged from 19.5 to 28.6 ng/g. Notably,
iAs was the main As species, accounting for 70 to 80% of the total As in the diet. Body weights
of mice in each group were measured prior to exposure and every two weeks thereafter until
the conclusion of the study (Fig 2A). Although weight gains were not significantly different
between groups at 8 weeks, mice in the 50 ppm group appeared to stop gaining weight between
weeks 4 and 6. However, this trend did not reach statistical significance. Mice in the control
group gained in average 7.3 g through week 8 (Fig 2B) as compared to 7.5 g and 5.3 g for mice
in the 25 ppm and 50 ppm groups, respectively (Fig 2B). Additionally, no significant
differences were noted in liver weights between experimental groups (data not shown). No
obvious signs of pathology were noted in dissected tissues.
Effect of iAs exposure on glucose tolerance
To determine the effects of iAsIII ingestion on glucose tolerance, mice in all exposure groups
were subjected to IPGTT (Fig 3). No significant differences in fasting blood glucose
concentrations were noted prior to glucose administration. All groups exhibited the
characteristic rapid rise in blood glucose within 15–30 min of glucose challenge, followed by
a gradual decrease in blood glucose concentrations that began 30 min after injection and
approached baseline levels by 120 min. The 50 ppm group experienced the greatest increase
in blood glucose concentration, reaching 24.6 mmol/L 15 min post injection, which was
significantly higher than the peak blood glucose concentration of 16.9 mmol/L in the control
group. Blood glucose levels in the 50 ppm group remained significantly higher than those of
control mice at 30 and 60 min after injection. No significant differences were noted between
control and 50 ppm groups at 90 and 120 min post injection or between control and 25 ppm
groups anytime during the IPGTT.
Concentrations of As species in mouse tissues
Traces of arsenicals were detected in tissues of control mice that were exposed only to As from
the diet. The concentrations of total speciated As in adipose tissue, pancreas, skeletal muscle,
and liver increased proportionally with the intake of iAs from drinking water (Fig 4). The
concentrations of total speciated As were 1.8- to 3.7-fold higher in tissues of mice in the 50
ppm group as compared to mice in the 25 ppm group. For both groups, the highest
concentrations of total speciated As were found in the liver and the lowest in adipose tissue.
The results of As speciation in tissues from mice in all three experimental groups are shown
in Figure 5. Notably, tissues of control mice contained almost exclusively iAs (Fig 5A). In this
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group of mice, the highest levels of iAsV were found in adipose tissue, followed by skeletal
muscle, liver and pancreas. In contrast, tissues of mice from the 25 ppm (Fig 5B) and 50 ppm
groups (Fig 5C) contained iAsV, MAsV and DMAsV. TMAsVO was not detected in tissues of
mice in either the 25 or 50 ppm groups. DMAsV was the predominant As species in all tissues
collected from mice in these groups. However, in the liver a significant fraction of As was
represented by iAsV: 39.8 and 29.4% for the 25 and 50 ppm groups, respectively. To examine
the recovery of As during the HG-AAS analysis, total As content was determined in livers and
skeletal muscle from mice in the 50 ppm group, using GF-AAS. Based on the comparison of
the HG-AAS and GF-AAS data, the average recovery of As was 110% for skeletal muscle and
105% for the liver. Because of limited access to GF-AAS, total As concentration was not
measured in pancreas or adipose tissue.
Discussion
Impaired glucose tolerance, an early indicator of insulin resistance and diabetes mellitus,
signifies the inability of peripheral tissues to perform glucose uptake at rates that are sufficient
to prevent excessive post-prandial blood glucose elevations. Previous reports on the effects of
As exposure on glucose homeostasis and in vivo insulin and carbohydrate metabolism in
laboratory animals have been inconsistent due in part to variations in choice of animal species
(mice, rats, goats) and arsenicals (iAsIII, iAsV, MAsIII, and MAsV), as well as the route (i.p.
vs. p.o.), concentration (0.025 ppm – 1,300 ppm), and duration (7 days – 2 years) of exposure.
The present study introduces a viable mouse model to investigate in vivo diabetogenic effects
of chronic exposures to iAs in drinking-water. We chose the C57BL/6 mouse strain for this
study because of its low baseline occurrence of type 2 diabetes but high susceptibility to the
development of diet-induced type 2 diabetes (Petro et al., 2004; Surwit et al., 1995; Surwit et
al., 1988). Our results show that 8-week exposure of C57BL/6 mice to 50 ppm iAsIII in
drinking-water promotes impaired glucose tolerance, which is consistent with diabetes
mellitus. However, the concentration of iAs in drinking water needed to produce this effect is
an order of magnitude higher than iAs concentrations shown to produce arseniasis symptoms,
including diabetes, in humans. For example, in arseniasis-endemic areas of Bangladesh, the
concentration of iAs in drinking water can reach 3.4 ppm (Alam et al., 2002). Liver samples
from local residents who developed hepatomegaly as a result of drinking water with 0.22 to 2
ppm iAs contained from 500 to 6,000 μg As/kg dry weight (Mazumder, 2005). This
corresponds to approximately 100 to 1,200 μg As/kg of intact liver. In our studies, similar
concentrations of total speciated As were found in livers of mice drinking water with 25 and
50 ppm iAsIII: 423 and 1165 μg As/kg, respectively. Results of an independent study carried
out in this laboratory showed that livers of mice exposed to 1 or 10 ppm iAsIII in drinking water
for 8 weeks contained on average only 11 and 155 μg As/kg, respectively (Paul et al.,
unpublished data). These data suggest that mice metabolize iAs and clear iAs metabolites from
tissues more efficiently than humans and that significantly higher exposure levels or longer
exposure times are needed in mice to produce symptoms of chronic As toxicity found in
humans.
It should be noted that the concentrations of iAs metabolites in tissues of mice in the 25 ppm
and 50 ppm groups (Fig. 5B,C) were not in proportion with the corresponding estimated intakes
of iAs from drinking water (Fig. 1C). The tissue concentrations of iAs metabolites in the 50
ppm group were several fold greater than in the 25 ppm group, despite a relatively small
difference in iAs intake. This may be, in part, due to significantly lower water consumption by
mice in the 50 ppm as compared to the 25 ppm group. (Fig. 1A,B). The smaller amount of
water consumed daily by mice in the 50 ppm group would result in a decreased urine production
and possibly, in a less efficient excretion of iAs metabolites in the urinary tract. Thus, the
profound increase in tissue retention of iAs metabolites in the 50 ppm as compared to the 25
ppm group may be a combined effect of the increased iAs intake and the impaired clearance
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of iAs metabolites due to lower water consumption. The disproportional increase in the tissue
concentrations of iAs metabolites in the 50 ppm group may explain why mice in this group
developed impaired glucose tolerance while mice in the 25 ppm group exhibit normal pattern
for glucose utilization.
As shown in Fig. 1, mice in both 25 and 50 ppm groups consumed significantly less water than
did control mice. Although mice are generally resistant to a prolonged dehydration (Haines et
al., 1978), it is unclear if the decreased water intake could directly contribute to the impaired
glucose tolerance in mice exposed to 50 ppm iAs. The potential role of dehydration in
modulating glucose metabolism and insulin sensitivity has been the subject of several studies.
In vitro studies have suggested that dehydration on the cellular level may disrupt insulin
signaling and glucose metabolism via mechanisms related to cell volume (Schliess and
Haussinger, 2003, 2000). However, a recent study suggests that dehydration does not
significantly impair insulin sensitivity or glucose metabolism in human subjects (Keller et
al., 2003). With no clear consensus regarding the effects of dehydration on glucose tolerance,
future studies should address this potential confounding factor when examining the effects of
chronic exposures to iAs or other arsenicals in drinking water.
Although the present study shows that mice exposed to iAs in drinking water develop impaired
glucose tolerance, the mechanisms underlying this outcome remain unclear. We have
previously shown that trivalent arsenicals, the metabolites of iAs, are potent inhibitors of
insulin-stimulated glucose uptake in cultured adipocytes (Paul et al., submitted; Walton et
al., 2004). Subtoxic concentrations of iAsIII and MAsIII inhibited the insulin-dependent
phosphorylation of PKB/Akt by PDK-1 and p-PKB/Akt-dependent translocation of GLUT4
to the plasma membrane. In contrast, DMAsIII inhibited GLUT4 translocation by a PKB/Akt-
independent mechanism. Thus, it is plausible that the same mechanisms are responsible for
impaired glucose tolerance in mice exposed to iAs in drinking water. However, inhibition of
insulin production in pancreatic β-cells by iAs or its metabolites may contribute to the overall
diabetogenic effects of iAs exposure. Future laboratory studies will clarify whether the
impaired glucose tolerance results from the inhibition of insulin signaling and/or decreased
insulin production by β-cells in this mouse model. Evaluation of these mechanisms with respect
to tissue concentrations and the level of exposure to iAs and its metabolites will help to improve
designs for future epidemiologic studies examining the association between the exposure to
iAs in drinking water, the individual pattern of iAs metabolism, and the risk of developing
diabetes mellitus.
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Water consumption by mice in the treatment groups: (A) Changes in the daily water
consumption by mice exposed to 25 ppm As (●) and 50 ppm As (■) and by control mice (□).
(B) The average daily consumption of water by mice in the control, 25 ppm, and 50 ppm groups.
(C) Estimated average intake of As by mice in the 25 ppm and 50 ppm groups. (Mean and SD,
n = 5.) *Value is significantly different (P < 0.05) from that in the control group.
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Body weights of mice in the treatment groups: (A) Changes in the body weights of mice
exposed to 25 ppm As (●) and 50 ppm As (■) and control mice (□) (Mean ± SD, n = 5). (B)
The average body weights of mice in the control, 25 ppm, and 50 ppm groups at the beginning
(□) and the end (■) of the study. (Mean and SD, n = 5.)
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Glucose concentrations in the blood of mice before and during the intraperitoneal glucose
tolerance test: Mice exposed to 25 ppm As (●) and 50 ppm As (■) and control mice (□). (Mean
± SD, n = 5.) *Value is significantly different (P < 0.05) from that in the control group.
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Dose-dependent increases in the total speciated As (iAsV + MAsV + DMAsV) levels in adipose
tissue (◆), pancreas (■), skeletal muscle (●), and liver (▲) of mice exposed to 25 ppm and
50 ppm As. (Mean ± SD, n = 5.)
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Arsenic species in adipose tissue, skeletal muscle, pancreas, and livers of control mice (A) and
mice exposed to 25 ppm As (B) and 50 ppm As (C): iAsV (■), MAsV (□) and DMAsV (▨).
(Mean; n = 5 for adipose tissue, skeletal muscle, and liver; n = 3 for pancreas.)
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